Phase II study for patient with Philadelphia chromosome positive acute lymphoblastic leukemia to determin the role of Dasatinb combined chemotherapy and allogeneic stem cell transplantation (PHII PHD)
Latest Information Update: 10 Feb 2025
At a glance
- Drugs Dasatinib (Primary)
- Indications Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- Acronyms PHII PHD
Most Recent Events
- 06 Feb 2025 Planned End Date changed from 31 Mar 2020 to 1 Dec 2027.
- 06 Feb 2025 Planned primary completion date changed to 1 Feb 2027.
- 02 Nov 2016 Status changed from not yet recruiting to recruiting.